

**SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE
THERAPEUTIC STUDIES ONLY (TXCA=Y)
73% of Calendar Year is Past**

<u>COMMITTEE</u>	<u>Base Accrual 2010</u>	<u>2017 Accrual to date</u>	<u>Percentage of Base Accrual</u>	<u>Projected 2017 Accrual</u>	<u>Projected Increase <Decrease> from Base</u>	<u>Accrual Last 12 Months</u>	<u>12 Month Increase <Decrease> from Base</u>
BREAST	1558	1036	66%	1426	-131	1325	-233
ERLYTX	76	178	234%	245	169	216	140
GI	476	159	33%	219	-257	215	-261
GU	450	328	73%	451	1	470	20
GYN	57	0	0%	0	-57	0	-57
LEUK	150	55	37%	75	-74	80	-70
LUNG	524	252	48%	347	-176	340	-184
LYMPH	172	4	2%	5	-166	8	-164
MELAN	55	814	1480%	1121	1066	1076	1021
MMYEL	147	52	35%	71	-75	81	-66
OTHER	0	23		31	31	34	34
Total	3665	2901		3991	331	3845	180

**SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE
NON-THERAPEUTIC STUDIES ONLY (TXCA=N)
73% of Calendar Year is Past**

<u>COMMITTEE</u>	<u>Base Accrual 2010</u>	<u>2017 Accrual to date</u>	<u>Percentage of Base Accrual</u>	<u>Projected 2017 Accrual</u>	<u>Projected Increase <Decrease> from Base</u>	<u>Accrual Last 12 Months</u>	<u>12 Month Increase <Decrease> from Base</u>
	0	1		1	1	1	1
BREAST	37	22	59%	30	-6	24	-13
CCD	0	1156		1592	1592	1579	1579
GU	0	0		0	0	0	0
LEUK	69	4	6%	5	-63	5	-64
LUNG	43	407	947%	560	517	573	530
LYMPH	53	0	0%	0	-53	0	-53
MMYEL	92	0	0%	0	-92	0	-92
OTHER	0	11		15	15	12	12
PREV	0	61		84	84	79	79
SURV	0	60		82	82	72	72
<u>SXQOL</u>	<u>878</u>	<u>12</u>	<u>1%</u>	<u>16</u>	<u>-861</u>	<u>30</u>	<u>-848</u>
Total	1172	1734		2385	1216	2375	1203

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE
ALL ACCRUAL REGISTRATIONS
73% of Calendar Year is Past

<u>COMMITTEE</u>	<u>Base Accrual 2010</u>	<u>2017 Accrual to date</u>	<u>Percentage of Base Accrual</u>	<u>Projected 2017 Accrual</u>	<u>Projected Increase <Decrease> from Base</u>	<u>Accrual Last 12 Months</u>	<u>12 Month Increase <Decrease> from Base</u>
	0	1		1	1	1	1
BREAST	1595	1058	66%	1457	-137	1349	-246
CCD	0	1156		1592	1592	1579	1579
ERLYTX	76	178	234%	245	169	216	140
GI	476	159	33%	219	-257	215	-261
GU	450	328	73%	451	1	470	20
GYN	57	0	0%	0	-57	0	-57
LEUK	219	59	27%	81	-137	85	-134
LUNG	567	659	116%	907	340	913	346
LYMPH	225	4	2%	5	-219	8	-217
MELAN	55	814	1480%	1121	1066	1076	1021
MMYEL	239	52	22%	71	-167	81	-158
OTHER	0	34		46	46	46	46
PREV	0	61		84	84	79	79
SURV	0	60		82	82	72	72
SXQOL	878	12	1%	16	-861	30	-848
Total	4837	4635		6378	1546	6220	1383

**SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE
THERAPEUTIC REGISTRATIONS BY SWOG INSTITUTIONS ONLY (TXCA=Y)
73% of Calendar Year is Past**

<u>COMMITTEE</u>	<u>Base Accrual 2010</u>	<u>2017 Accrual to date</u>	<u>Percentage of Base Accrual</u>	<u>Projected 2017 Accrual</u>	<u>Projected Increase <Decrease> from Base</u>	<u>Accrual Last 12 Months</u>	<u>12 Month Increase <Decrease> from Base</u>
BREAST	1012	434	43%	597	-414	534	-478
ERLYTX	76	121	159%	166	90	159	83
GI	418	120	29%	165	-252	169	-249
GU	375	236	63%	325	-49	326	-49
GYN	57	0	0%	0	-57	0	-57
LEUK	122	42	34%	57	-64	64	-58
LUNG	441	170	39%	234	-206	227	-214
LYMPH	129	4	3%	5	-123	8	-121
MELAN	55	426	775%	586	531	563	508
MMYEL	85	52	61%	71	-13	81	-4
OTHER	0	23		31	31	34	34
Total	2770	1628		2237	-526	2165	-605

**SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE
NON-THERAPEUTIC STUDIES FOR SWOG INSTITUTIONS ONLY (TXCA=N)
73% of Calendar Year is Past**

<u>COMMITTEE</u>	<u>Base Accrual 2010</u>	<u>2017 Accrual to date</u>	<u>Percentage of Base Accrual</u>	<u>Projected 2017 Accrual</u>	<u>Projected Increase <Decrease> from Base</u>	<u>Accrual Last 12 Months</u>	<u>12 Month Increase <Decrease> from Base</u>
BREAST	10	22	220%	30	20	24	14
CCD	0	1011		1392	1392	1434	1434
GU	0	0		0	0	0	0
LEUK	69	4	6%	5	-63	5	-64
LUNG	30	287	957%	395	365	376	346
LYMPH	53	0	0%	0	-53	0	-53
MMYEL	92	0	0%	0	-92	0	-92
OTHER	0	11		15	15	12	12
PREV	0	49		67	67	60	60
SURV	0	36		49	49	46	46
<u>SXQOL</u>	<u>740</u>	<u>12</u>	<u>2%</u>	<u>16</u>	<u>-723</u>	<u>30</u>	<u>-710</u>
Total	994	1432		1969	977	1987	993

**SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE
ALL ACCRUAL REGISTRATIONS BY SWOG INSTITUTIONS ONLY
73% of Calendar Year is Past**

<u>COMMITTEE</u>	<u>Base Accrual 2010</u>	<u>2017 Accrual to date</u>	<u>Percentage of Base Accrual</u>	<u>Projected 2017 Accrual</u>	<u>Projected Increase <Decrease> from Base</u>	<u>Accrual Last 12 Months</u>	<u>12 Month Increase <Decrease> from Base</u>
BREAST	1022	456	45%	628	-393	558	-464
CCD	0	1011		1392	1392	1434	1434
ERLYTX	76	121	159%	166	90	159	83
GI	418	120	29%	165	-252	169	-249
GU	375	236	63%	325	-49	326	-49
GYN	57	0	0%	0	-57	0	-57
LEUK	191	46	24%	63	-127	69	-122
LUNG	471	457	97%	629	158	603	132
LYMPH	182	4	2%	5	-176	8	-174
MELAN	55	426	775%	586	531	563	508
MMYEL	177	52	29%	71	-105	81	-96
OTHER	0	34		46	46	46	46
PREV	0	49		67	67	60	60
SURV	0	36		49	49	46	46
SXQOL	740	12	2%	16	-723	30	-710
Total	3764	3060		4208	451	4152	388

**SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE
ALL ACCRUAL REGISTRATIONS TO CANCER CONTROL STUDIES
73% of Calendar Year is Past**

<u>COMMITTEE</u>	<u>Base Accrual 2010</u>	<u>2017 Accrual to date</u>	<u>Percentage of Base Accrual</u>	<u>Projected 2017 Accrual</u>	<u>Projected Increase <Decrease> from Base</u>	<u>Accrual Last 12 Months</u>	<u>12 Month Increase <Decrease> from Base</u>
BREAST	65	878	1351%	1209	1144	1144	1079
CCD	0	1156		1592	1592	1579	1579
GI	81	24	30%	33	-47	38	-43
GU	215	54	25%	74	-140	66	-149
LEUK	0	4		5	5	5	5
LUNG	53	79	149%	108	55	128	75
LYMPH	7	1	14%	1	-5	3	-4
MELAN	0	743		1023	1023	984	984
MMYEL	0	52		71	71	81	81
OTHER	0	18		24	24	28	28
PREV	0	61		84	84	79	79
SURV	0	60		82	82	72	72
<u>SXQOL</u>	<u>878</u>	<u>12</u>	<u>1%</u>	<u>16</u>	<u>-861</u>	<u>30</u>	<u>-848</u>
Total	1299	3142		4322	3027	4237	2938

SWOG OPEN AND TEMPORARILY CLOSED STUDIES

Comm.	Phase	Study	Stat Center	Open Date	Months Open	Total Regs	Accrual Goal	Monthly Accrual Rate	Date of Expected Closure or Temporary Closure
		NRGBR002	NRG			1			
BREAST	II	S1416 Brst, TNBC/BRCA, Cis+/- ABT-888	SWOG	07JUL2016:00:00:00	14	135	333	14.3	Oct-2018
	III	A011106 Breast, Neoadj, ALTERNATE study	ALLIANCE	15FEB2014:00:00:00		49		2.8	
		A011202 Breast, Nodal XRT +/- ALND	ALLIANCE			54			
		A011401 Breast, adj, Stage II/III HER2-, weight loss	ALLIANCE	29AUG2016:00:00:00		74		8.5	
		A011502 Brst, Adj, Nodal+&HER2-, Aspirin vs. Placebo	ALLIANCE	08DEC2016:00:00:00		14		2.2	
		B51 Breast, Regional Nodal XRT	NRG			18			
		B55 Brst, Adj Olaparib for BRCA,TNBC	NRG	03JUL2014:00:00:00		18		0.5	
		E2112 Brst,Adv,Exemestane+/-Entinostat	ECOG-ACR	02JAN2014:00:00:00		39		1.7	
		NRGBR003 Brst,Adj,TNBC,AC -> WP +/- Carbo	NRG	22JAN2015:00:00:00		42		2.5	
		S1007 Breast,Adj,N1,Endocrine+/-Chemo	SWOG	15JAN2011:00:00:00	80	5047	4000	43.0	Sep-2015
		S1207 Brst,Adj,Endocrine+/-Everolimus	SWOG	03SEP2013:00:00:00	48	1356	1900	35.8	Dec-2018
		S1222 Brst,Fulv. +/- Ever. +/- Anastr.	SWOG	09MAY2014:00:00:00		37	840		Feb-2015 Temp Close
		S1418 Breast, Adj, TNBC, MK-3475 (Pembrolizumab)	SWOG	15NOV2016:00:00:00	10	66	1000	10.2	Apr-2025
OTHER		A221405 Breast, ET interruption, Pregnancy Outcomes	ALLIANCE	15OCT2015:00:00:00		2		0.3	
		E1Z11 Brst,Genetic Predictors of AIMSS	ECOG-ACRIN	10MAY2013:00:00:00		144		1.0	
CCD	III	A011104 Preoperative Breast MRI	ALLIANCE	21FEB2014:00:00:00		10		0.5	
		S1415CD TrACER CSF Standing Order Intervention for FN	SWOG	01SEP2016:00:00:00	12	895	3960	110.3	Dec-2019
OTHER		S1417CD Colorectal, Cost Cohort Study	SWOG	13MAY2016:00:00:00	16	106	374	12.5	Jun-2019
ERLYTX	II	A071401 Prog Meningiomas,SMO/AKT/NF2 Inhib	ALLIANCE	06AUG2015:00:00:00		5		0.0	
		S1609 Rare Tumor, Comb Nivo/Ipi	SWOG	13JAN2017:00:00:00	8	124	636	18.3	Dec-2019
	II-III	A071102 GBM, adj TMZ +/- Veliparib	ALLIANCE	19SEP2014:00:00:00		37		0.0	
		ARST1321 NonRhabdo STS,Pazopanib (PAZNTIS)	COG	16MAY2014:00:00:00		4		0.3	
OTHER		EAY131 MATCH	ECOG-ACR	12AUG2015:00:00:00		97		5.3	
GI	II	A021501 Adeno Panc,Borderline Resect,Chemo vs ChemoRT	ALLIANCE	01DEC2016:00:00:00		8		1.3	
		EA2133 Anal, local recur/met, Cis+5FU vs Taxol/Carbo	ECOG-ACRIN	29JAN2016:00:00:00		1		0.0	
		EA2142 GI NEC, Adv G3, EP vs TMZ + CAP	ECOG-ACRIN	06NOV2015:00:00:00		4		0.5	
		NRGGI002 Rectal, Ph II, Sensitization using TNT	NRG	12OCT2016:00:00:00		2		0.2	
		S1505 Panc,Resect, Perioperative Chemo	SWOG	12OCT2015:00:00:00	23	92	112	2.2	Jun-2018
		S1513 Panc, Met, FOLFIRI vs mFOLFIRI + ABT-888	SWOG	01SEP2016:00:00:00	12	88	143	11.5	Jan-2018
	II-III	N1048 Rectal,LocalAdv,ChemoRT+/-FOLFOX	ALLIANCE	13JAN2012:00:00:00		129		3.3	
	III	R0848 Panc, Adj, Erlotinib v ChemoRT	NRG	01MAR2014:00:00:00		20		0.0	
GU	II	EA8141 UTUC, HG, Chemo then Surg	ECOG-ACR	27JAN2015:00:00:00		8		0.3	
		S1314 Blad, COXEN Neoadj. Chemo + Cyst	SWOG	11JUL2014:00:00:00	38	224	230	9.3	Sep-2017
		S1500 pRCC,Adv, Sunitinib vs MET inhib	SWOG	05APR2016:00:00:00	17	50	180	3.0	Apr-2021

SWOG OPEN AND TEMPORARILY CLOSED STUDIES

Comm.	Phase	Study	Stat Center	Open Date	Months Open	Total Regs	Accrual Goal	Monthly Accrual Rate	Date of Expected Closure or Temporary Closure
		S1605 Blad, BCG-Unresponsive NMIBC, Atezolizumab	SWOG	07FEB2017:00:00:00	7	11	148	1.7	Jul-2024
	II-III	NRGGU002 Pros, RT + ADT After RP +/- Adj Docetaxel	NRG	30DEC2016:00:00:00		1		0.2	
	III	A031102 GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE)	ALLIANCE	01JUL2015:00:00:00		2		0.0	
		R0924 Pros, NADT+WPRT vs. NADT+P&SV RT	NRG	07JUL2011:00:00:00		52		2.0	
		S1602 Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG	SWOG	07FEB2017:00:00:00	7	32	969	5.2	> 15 Yrs
LEUK	I	S1312 ALL, CD22+, REL/REF, Inotuzumab+CVP	SWOG	01APR2014:00:00:00	41	37	38	0.5	Oct-2017
	I-II	S1318 ALL, Age 65+, Ph±, Blinatumomab	SWOG	12JAN2015:00:00:00	32	47	44	3.3	Sep-2017
	III	E1910 BCR-ABL-neg, B ALL, Blinatumomab	ECOG-ACRIN	23DEC2013:00:00:00		66		2.3	
		E2906 AML, Age 60+, Clo vs Dauno+Cy	ECOG-ACRIN	24FEB2011:00:00:00		75		0.0	
	OTHER	NHLBIMDS LEUK, National MDS Study	ECOG-ACRIN	05APR2016:00:00:00		5		0.5	
LUNG	I-II	8811 NSCLC, Stage III,ChemoRT+ABT-888	SWOG	02JAN2013:00:00:00	56	53	162	3.2	Jul-2020
	II	R1306 NSCLC,Adv,ALK/EGFR,TargetAgents	NRG	04NOV2013:00:00:00		8		0.0	
		S1400G HRRD: Talazoparib (BMN 673)	SWOG	07FEB2017:00:00:00	7	29	60	4.7	Mar-2018
		S1507 NSCLC, Adv, Kras Mut, Trametinib + Docetaxel	SWOG	18JUL2016:00:00:00	14	37	53	2.8	Feb-2018
	II-III	NRGCC003 SCLC, PCI or HA-PCI	NRG	07DEC2015:00:00:00		4		0.5	
		S1403 Adv,EGFR-mt,Afatinib+/-Cetuximab	SWOG	25MAR2015:00:00:00	29	139	605	7.7	Sep-2022
	III	A081105 ALCHEMIST1, EGFR mut, Erlotinib	ALLIANCE	02JAN2014:00:00:00		25		1.5	
		C30610 SCLC, Thoracic RT	ALLIANCE	21MAR2008:00:00:00		52		0.3	
		E4512 ALCHEMIST2, ALK mut, Crizotinib	ECOG-ACR	18AUG2014:00:00:00		5		0.3	
		EA5142 ALCHEMIST3, Non-match, Nivolumab	ECOG-ACRIN	16MAY2016:00:00:00		22		2.3	
		S1400I Non-Match: Nivo + Ipi vs Nivo	SWOG	18DEC2015:00:00:00	21	229	350	8.7	Oct-2018
	OTHER	A151216 ALCHEMIST0 - screening	ALLIANCE	06FEB2014:00:00:00		365		17.5	
		S1400 SCCA,Adv, Biomarker Master	SWOG	15JUN2014:00:00:00	39	1378		30.7	
LYMPH	II	S1608 Rel/Ref FL, TGR-1202/Lenalidomide/CHOP + Ob	SWOG	10AUG2017:00:00:00	1	0	150		
	III	A051301 ABC DLBCL, Auto HCT and Ibrutinib/Placebo	ALLIANCE	15JUL2016:00:00:00		2		0.3	
MELAN	II	E3612 MELAN,Adv Ipilimumab±Bevacizumab	ECOG-ACR			6			
		S1320 Adv, BRAF mut, Inter v Contin	SWOG	22JUL2014:00:00:00	38	171	280	5.7	Apr-2019
		S1512 Melan, Adv, Desmoplastic, MK-3475 (pembro)	SWOG	20OCT2016:00:00:00	11	3	77	0.3	> 15 Yrs
		S1616 MELAN,, Adv, Ipilimumab ± Nivolumab	SWOG	17JUL2017:00:00:00	2	0	94		
	II-III	EA6141 Melan, Avd, Nivolumab+Ipi ± Sargmostim	ECOG-ACRIN	01MAR2016:00:00:00		36		3.0	
	III	EA6134 Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T	ECOG-ACR	15DEC2015:00:00:00		19		0.7	
		S1404 Melan, Adv, HD-IFN/Ipilimumab vs MK-3475	SWOG	15OCT2015:00:00:00	23	1345	1378	82.0	Sep-2017
MMYEL	I-II	S1211 MM,High Risk, RVD+/-ELO	SWOG	27OCT2012:00:00:00		142	110		Jun-2016 Temp Close
	III	E1A11 MM, frontline, BLD vs CLD	ECOG-ACRIN	22NOV2013:00:00:00		137		5.2	
OTHER	I-II	A091304 Adv Sarc, MLN0128 v Pazopanib, Phi/II	ALLIANCE	26JAN2015:00:00:00		6		0.7	

SWOG OPEN AND TEMPORARILY CLOSED STUDIES

Comm.	Phase	Study	Stat Center	Open Date	Months Open	Total Regs	Accrual Goal	Monthly Accrual Rate	Date of Expected Closure or Temporary Closure
	II	A091202 Sarc, Efatutazone vs Placebo, Unresect ,Lipo	ALLIANCE	02SEP2014:00:00:00		2		0.2	
		A091305 HN, Adv, Thyroid PPAR agonist + Chemo	ALLIANCE	01SEP2014:00:00:00		2		0.0	
		A091401 Sarc,	ALLIANCE	18JUN2015:00:00:00		5		0.0	
		A091404 HN, AR+, Enzalutamide	ALLIANCE	25SEP2015:00:00:00		5		0.7	
		EA3132 HN SCC, Stg III-IV , Adj RT +/- Cisp	ECOG-ACRIN	29MAR2016:00:00:00		2		0.3	
		NRGBN001 HN, novel vs. std chemoradiation + chemo	NRG	28AUG2015:00:00:00		1		0.0	
	II-III	G0281 Ovar, Recur/prog LG, IC chemo vs trametinib	NRG	27FEB2014:00:00:00		1		0.2	
		G0286B Adv Endometrial, Metformin/Chemo	NRG			1			
		NRGGY005 OVAR, Cedir vs Olaparib vs C+O vs Std of Care	NRG	06FEB2016:00:00:00		3		0.2	
		NRGHN001 Nasopharyngeal , Individual Tx EBV	NRG	21APR2014:00:00:00		3		0.2	
		R1216 HN, Adv, Cis vs Dtx vs Dtx+Cetux	NRG	18MAR2013:00:00:00		3		0.0	
	III	G0263 Cerv, Stg I/IIA, adjv RT vs chemoRT	NRG	12APR2010:00:00:00		1		0.2	
		N0577 BRN, Glio, Tem vs Tem+RT vs RT+PVC	ALLIANCE			4			
		NRGGY004 Ovar, Recur HG, VEGFi vs VEGFi+PARPi vs chemo	NRG	04FEB2016:00:00:00		4		0.2	
		R0724 Cervical, Chem+RT +/- Adj. Chemo	NRG	15JAN2014:00:00:00		1		0.0	
		R0920 HN, Adv, Postop IMRT ± Cetuximab	NRG	24DEC2013:00:00:00		10		0.0	
	OTHER	EAQ152 Communication & education in tumor profiling	ECOG-ACR	26SEP2016:00:00:00		11		0.8	
PREV	II	EA1141 Breast, Abbrev. MRI vs Digital Tomosynthesis	ECOG-ACR	02SEP2016:00:00:00		18		3.0	
	III	A211102 Breast, Atypia via RPFNA, Metformin v Placebo	ALLIANCE	01FEB2015:00:00:00		3		0.2	
		S0820 PACES: ColrecStg0-3 Blind DFMO/Sulindac	SWOG	01MAR2013:00:00:00	54	161	480	5.0	Dec-2022
	OTHER	A211201 Breast Density, MA.32 companion	ALLIANCE	22AUG2012:00:00:00		14		0.0	
SURV	III	E1Q11 EROS: Reproductive Health in Cancer Survivors	ECOG-ACR	30SEP2015:00:00:00		6		0.7	
		S1501 Surv, Breast Stg IV, Card Tox w/ Carvedilol	SWOG	15SEP2017:00:00:00	0	0	817		
	OTHER	S1316 Compar. Effectiv. Trial for MBO	SWOG	09MAR2015:00:00:00	30	110	200	7.0	Sep-2018
SXQOL	III	A221101 Glioma, Nuvigil/Placebo Fatigue	ALLIANCE	03JUN2013:00:00:00		17		0.5	
		A221102 Brst, AI Arthralgia, Testosterone	ALLIANCE	07SEP2012:00:00:00		10		0.0	

Accrual goals assume studies are not terminated early as a result of interim analysis.

Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.

Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months.

Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.

OPEN AND TEMPORARILY CLOSED STUDIES: BY STUDY TYPE, COMMITTEE, INTERGROUP, SWOG/OTHER STAT CENTER

Phase	Comm.	Int grp	Stat Center	Study	NCIPROTO	CA Cntrl Study	Temp Close
OTHER	BREAST	Y	ECOG-ACRIN	E1Z11 Brst,Genetic Predictors of AIMSS	E1Z11	Y	
		Y	ALLIANCE	A221405 Breast, ET interruption, Pregnancy Outcomes	A221405	Y	
	CCD	N		S1417CD Colorectal, Cost Cohort Study		Y	
	ERLYTX	Y	ECOG-ACR	EAY131 MATCH	EAY131	N	
	LEUK	Y	ECOG-ACRIN	NHLBIMDS LEUK, National MDS Study	NHLBI-MDS	Y	
	LUNG	Y	SWOG	S1400 SCCA,Adv, Biomarker Master	S1400	N	
		Y	ALLIANCE	A151216 ALCHEMIST0 - screening	A151216	N	
	OTHER	Y	ECOG-ACR	EAQ152 Communication & education in tumor profiling	EAQ152	Y	
	PREV	Y	ALLIANCE	A211201 Breast Density, MA.32 companion	A211201	Y	
	SURV	Y	SWOG	S1316 Compar. Effectiv. Trial for MBO	S1316	Y	
I	LEUK	N		S1312 ALL, CD22+, REL/REF, Inotuzumab+CVP		N	
I-II	LEUK	Y	SWOG	S1318 ALL, Age 65+, Ph±, Blinatumomab	S1318	N	
	LUNG	Y	SWOG	8811 NSCLC, Stage III,ChemoRT+ABT-888	8811	N	
	MMYEL	Y	SWOG	S1211 MM,High Risk, RVD+/-ELO	S1211	N	Y
	OTHER	Y	ALLIANCE	A091304 Adv Sarc, MLN0128 v Pazopanib, Ph/II	A091304	N	
II	BREAST	Y	SWOG	S1416 Brst, TNBC/BRCA, Cis+/- ABT-888	S1416	N	
	ERLYTX	Y	SWOG	S1609 Rare Tumor, Comb Nivo/Ipi	S1609	N	
		Y	ALLIANCE	A071401 Prog Meningiomas,SMO/AKT/NF2 Inhib	A071401	N	
	GI	Y	SWOG	S1513 Panc, Met, FOLFIRI vs mFOLFIRI + ABT-888	S1513	N	
		Y	SWOG	S1505 Panc,Resect, Perioperative Chemo	S1505	N	
		Y	ECOG-ACRIN	EA2142 GI NEC, Adv G3, EP vs TMZ + CAP	EA2142	N	
		Y	NRG	NRGGI002 Rectal, Ph II, Sensitization using TNT	NRG-GI002	N	
		Y	ALLIANCE	A021501 Adeno Panc,Borderline Resect,Chemo vs ChemoRT	A021501	N	
		Y	ECOG-ACRIN	EA2133 Anal, local recur/met, Cis+5FU vs Taxol/Carbo	EA2133	Y	
	GU	Y	SWOG	S1314 Blad, COXEN Neoadj. Chemo + Cyst	S1314	N	
		Y	SWOG	S1500 pRCC,Adv, Sunitinib vs MET inhib	S1500	N	
		Y	SWOG	S1605 Blad, BCG-Unresponsive NMIBC, Atezolizumab	S1605	N	
		Y	ECOG-ACR	EA8141 UTUC, HG, Chemo then Surg	EA8141	N	
	LUNG	Y	SWOG	S1400G HRRD: Talazoparib (BMN 673)	S1400G	N	
		Y	SWOG	S1507 NSCLC, Adv, Kras Mut, Trametinib + Docetaxel	S1507	N	
		Y	NRG	R1306 NSCLC,Adv,ALK/EGFR,TargetAgents	RTOG-1306	N	
	LYMPH	Y	SWOG	S1608 Rel/Ref FL, TGR-1202/Lenalidomide/CHOP + Ob	S1608	N	
	MELAN	Y	SWOG	S1320 Adv, BRAF mut, Inter v Contin	S1320	N	
		Y	SWOG	S1616 MELAN,, Adv, Ipilimumab ± Nivolumab	S1616	N	
		Y	SWOG	S1512 Melan, Adv, Desmoplastic, MK-3475 (pembro)	S1512	N	
		Y	ECOG-ACR	E3612 MELAN,Adv Ipilimumab±Bevacizumab	E3612	N	
	OTHER	Y	NRG	NRGBN001 HN, novel vs. std chemoradiation + chemo	NRG-BN001	N	

OPEN AND TEMPORARILY CLOSED STUDIES: BY STUDY TYPE, COMMITTEE, INTERGROUP, SWOG/OTHER STAT CENTER

Phase	Comm.	Int grp	Stat Center	Study	NCIPROTO	CA Cntrl Study	Temp Close
		Y	ALLIANCE	A091202 Sarc, Efatutazone vs Placebo, Unresect ,Lipo	A091202	N	
		Y	ALLIANCE	A091401 Sarc,	A091401	N	
		Y	ALLIANCE	A091305 HN, Adv, Thyroid PPAR agonist + Chemo	A091305	N	
		Y	ALLIANCE	A091404 HN, AR+, Enzalutamide	A091404	N	
		Y	ECOG-ACRIN	EA3132 HN SCC, Stg III-IV , Adj RT +/- Cisp	EA3132	N	
	PREV	Y	ECOG-ACR	EA1141 Breast, Abbrev. MRI vs Digital Tomosynthesis	EA1141	Y	
II-III	ERLYTX	Y	ALLIANCE	A071102 GBM, adj TMZ +/- Veliparib	A071102	N	
		Y	COG	ARST1321 NonRhabdo STS,Pazopanib (PAZNTIS)	ARST1321	N	
	GI	Y	ALLIANCE	N1048 Rectal,LocalAdv,ChemoRT+/-FOLFOX	N1048	Y	
	GU	Y	NRG	NRGGU002 Pros, RT + ADT After RP +/- Adj Docetaxel	NRG-GU002	N	
	LUNG	Y	SWOG	S1403 Adv,EGFR-mt,Afatinib+/-Cetuximab	S1403	N	
		Y	NRG	NRGCC003 SCLC, PCI or HA-PCI	NRG-CC003	Y	
	MELAN	Y	ECOG-ACRIN	EA6141 Melan, Avd, Nivolumab+Ipi ± Sargmostim	EA6141	N	
	OTHER	Y	NRG	NRGGY005 OVAR, Cedir vs Olaparib vs C+O vs Std of Care	NRG-GY005	Y	
		Y	NRG	G0286B Adv Endometrial,Metformin/Chemo	GOG-0286B	Y	
		Y	NRG	R1216 HN, Adv,Cis vs Dtx vs Dtx+Cetux	RTOG-1216	Y	
		Y	NRG	NRGHN001 Nasopharyngeal , Individual Tx EBV	NRG-HN001	Y	
		Y	NRG	G0281 Ovar, Recur/prog LG, IC chemo vs trametinib	GOG-0281	Y	
III	BREAST	N		S1222 Brst,Fulv. +/- Ever. +/- Anastr.		N	Y
		Y	SWOG	S1207 Brst,Adj,Endocrine+/-Everolimus	S1207	Y	
		Y	SWOG	S1418 Breast, Adj, TNBC, MK-3475 (Pembrolizumab)	S1418	Y	
		Y	SWOG	S1007 Breast,Adj,N1,Endocrine+/-Chemo	S1007	Y	
		Y	ALLIANCE	A011202 Breast, Nodal XRT +/- ALND	A011202		
		Y	ALLIANCE	A011106 Breast, Neoadj, ALTERNATE study	A011106	N	
		Y	NRG	B51 Breast, Regional Nodal XRT	NSABP-B-51	Y	
		Y	ALLIANCE	A011401 Breast, adj, Stage II/III HER2-, weight loss	A011401	Y	
		Y	NRG	NRGBR003 Brst,Adj,TNBC,AC -> WP +/- Carbo	NRG-BR003	N	
		Y	ECOG-ACR	E2112 Brst,Adv,Exemestane+/-Entinostat	E2112	Y	
		Y	ALLIANCE	A011502 Brst, Adj, Nodal+HER2-, Aspirin vs. Placebo	A011502	Y	
		Y	NRG	B55 Brst, Adj Olaparib for BRCA,TNBC	NSABP-B-55	Y	
	CCD	Y	SWOG	S1415CD TrACER CSF Standing Order Intervention for FN	S1415CD	Y	
		Y	ALLIANCE	A011104 Preoperative Breast MRI	A011104	Y	
	GI	Y	NRG	R0848 Panc, Adj, Erlotinib v ChemoRT	RTOG-0848	Y	
	GU	Y	SWOG	S1602 Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG	S1602	Y	
		Y	NRG	R0924 Pros, NADT+WPRT vs. NADT+P&SV RT	RTOG-0924	Y	
		Y	ALLIANCE	A031102 GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE)	A031102	Y	
	LEUK	Y	ECOG-ACRIN	E2906 AML, Age 60+, Clo vs Dauno+Cy	E2906	Y	

OPEN AND TEMPORARILY CLOSED STUDIES: BY STUDY TYPE, COMMITTEE, INTERGROUP, SWOG/OTHER STAT CENTER

<u>Phase</u>	<u>Comm.</u>	<u>Int</u> <u>grp</u>	<u>Stat</u> <u>Center</u>	<u>Study</u>	<u>NCIPROTO</u>	<u>CA</u> <u>Cntrl</u> <u>Study</u>	<u>Temp</u> <u>Close</u>
		Y	ECOG-ACRIN	E1910 BCR-ABL-neg, B ALL, Blinatumomab	E1910	N	
LUNG		Y	SWOG	S1400I Non-Match: Nivo + Ipi vs Nivo	S1400I	Y	
		Y	ALLIANCE	C30610 SCLC, Thoracic RT	CALGB-30610	Y	
		Y	ALLIANCE	A081105 ALCHEMIST1, EGFR mut, Erlotinib	A081105	N	
		Y	ECOG-ACRIN	EA5142 ALCHEMIST3, Non-match, Nivolumab	EA5142	N	
		Y	ECOG-ACR	E4512 ALCHEMIST2, ALK mut, Crizotinib	E4512	N	
LYMPH		Y	ALLIANCE	A051301 ABC DLBCL, Auto HCT and Ibrutinib/Placebo	A051301	N	
MELAN		Y	SWOG	S1404 Melan, Adv, HD-IFN/Ipilimumab vs MK-3475	S1404	Y	
		Y	ECOG-ACR	EA6134 Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T	EA6134	Y	
MMYEL		Y	ECOG-ACRIN	E1A11 MM, frontline, BLD vs CLD	E1A11	Y	
OTHER		Y	NRG	R0920 HN, Adv, Postop IMRT ± Cetuximab	RTOG-0920	Y	
		Y	ALLIANCE	N0577 BRN, Glio,Tem vs Tem+RT vsRT+PVC	N0577	N	
		Y	NRG	G0263 Cerv, Stg I/IIA, adjv RT vs chemoRT	GOG-0263	Y	
		Y	NRG	R0724 Cervical, Chem+RT +/- Adj. Chemo	RTOG-0724	Y	
		Y	NRG	NRGGY004 Ovar, Recur HG, VEGFi vs VEGFi+PARPi vs chemo	NRG-GY004	Y	
PREV		Y	SWOG	S0820 PACES: ColrecStg0-3 Blind DFMO/Sulindac	S0820	Y	
		Y	ALLIANCE	A211102 Breast, Atypia via RPFNA, Metformin v Placebo	A211102	Y	
SURV		Y	SWOG	S1501 Surv, Breast Stg IV, Card Tox w/ Carvedilol	S1501	Y	
		Y	ECOG-ACR	E1Q11 EROS: Reproductive Health in Cancer Survivors	E1Q11	Y	
SXQOL		Y	ALLIANCE	A221101 Glioma, Nuvigil/Placebo Fatigue	A221101	Y	
		Y	ALLIANCE	A221102 Brst,AI Arthralgia,Testosterone	A221102	Y	
		Y	NRG	NRGBR002	NRG-BR002		

**PHASE III SWOG COORDINATED OPEN STUDIES
SORTED BY STUDY ID**

Protocol Number	Study	Accrual Goal	Open Stat/Date	Months Open	Accrual as of 01Jan02	Current Accrual	Proj. Annual Accr. Rate	EXPCLOSE	Proj. Study Duration (Years)
S0820 S0820	PACES: ColrecStg0-3 Blind DFMO/Sulindac (PREV)	480	Y-03/01/13	54	161	161	60	Dec-2022	9.8
S1007 S1007	Breast,Adj,N1,Endocrine+/-Chemo (BREAST)	4000	Y-01/15/11	80	5047	5047	516	Sep-2015	4.7
S1207 S1207	Brst,Adj,Endocrine+/-Everolimus (BREAST)	1900	Y-09/03/13	48	1356	1356	430	Dec-2018	5.3
S1222	Brst,Fulv. +/- Ever. +/- Anastr. (BREAST)	840	T-05/09/14	40	37	37	0	> 15 Yrs	> 15 Yrs
S1400I S1400I	Non-Match: Nivo + Ipi vs Nivo (LUNG)	350	Y-12/18/15	21	229	229	104	Oct-2018	2.8
S1403 S1403	Adv,EGFR-mt,Afatinib+/-Cetuximab (LUNG)	605	Y-03/25/15	29	139	139	92	Sep-2022	7.5
S1404 S1404	Melan, Adv, HD-IFN/Ipilimumab vs MK-3475 (MELAN)	1378	Y-10/15/15	23	1345	1345	984	Sep-2017	1.9
S1415CD S1415CD	TrACER CSF Standing Order Intervention for FN (CCD)	3960	Y-09/01/16	12	895	895	1324	Dec-2019	3.3
S1418 S1418	Breast, Adj, TNBC, MK-3475 (Pembrolizumab) (BREAST)	1000	Y-11/15/16	10	66	66	122	Apr-2025	8.4
S1501 S1501	Surv, Breast Stg IV, Card Tox w/ Carvedilol (SURV)	817	Y-09/15/17	0	0	0			
S1602 S1602	Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG (GU)	969	Y-02/07/17	7	32	32	62	> 15 Yrs	> 15 Yrs

Accrual goals assume studies are not terminated early as a result of interim analysis.

Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.

Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months.

Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.